shutterstock_1997869478_pla2na

Pla2na / Shutterstock.com

7 April 2022Sarah Gibbs

G 2/21: how to support inventive steps in patentability

Post-published evidence can be crucial to establishing patentability. G 2/21, the European Patent Office (EPO)’s referral to the Enlarged Board of Appeal (EBA) on the question of whether post-published evidence can be used to support the concept of “inventive step”.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

CRISPR: the shifting sands of patentability

12 November 2015 The patentability of any claims directed to the use of CRISPR technology in human embryo-like structures and human reproductive cells is far from certain, as Duncan Ribbons and Maeve Lynch of Redd explain.

Europe v US: the patentability of diagnostic claims

17 September 2015 Researchers should keep in mind that broad claims applying the discovery of a biomarker and disease correlation are currently patentable in Europe but not in the US. Andrew Carridge and Neil Thornton of Reddie & Grose report.

More on this story

CRISPR: the shifting sands of patentability

12 November 2015 The patentability of any claims directed to the use of CRISPR technology in human embryo-like structures and human reproductive cells is far from certain, as Duncan Ribbons and Maeve Lynch of Redd explain.

Europe v US: the patentability of diagnostic claims

17 September 2015 Researchers should keep in mind that broad claims applying the discovery of a biomarker and disease correlation are currently patentable in Europe but not in the US. Andrew Carridge and Neil Thornton of Reddie & Grose report.

More on this story

CRISPR: the shifting sands of patentability

12 November 2015 The patentability of any claims directed to the use of CRISPR technology in human embryo-like structures and human reproductive cells is far from certain, as Duncan Ribbons and Maeve Lynch of Redd explain.

Europe v US: the patentability of diagnostic claims

17 September 2015 Researchers should keep in mind that broad claims applying the discovery of a biomarker and disease correlation are currently patentable in Europe but not in the US. Andrew Carridge and Neil Thornton of Reddie & Grose report.

More features

China’s new policies on foreign investment in healthcare and biotech

Startup CFO’s betrayal is a lesson in preparing for the worst

LSPN Fall: Gilead GC shares top drafting tips

How post-filing data rescued Novo Nordisk’s Ozempic patent in China

How to navigate patent term adjustment in China

‘This is a big problem’: The CRISPR controversy and the ‘mess’ at the heart of the EPO’s appeals boards

Preventative IP for preventative pharma healthcare

Dexcom suffers second patent revocation at hands of UPC